Christopher G. Nasveschuk

Author

Constellation Pharmaceuticals (United States)ORCID

Also Known As

C. G Nasveschuk, C. G. Nasveschuk, C. Nasveschuk, Christopher G. Nasveschuk, Christopher G. Naveschuk, Christopher Nasveschuk, Christopher G. Nasveschuk, Nasveschuk, C.G., Nasveschuk, Christopher G.

Publications

Citations

H-Index

Concepts

All Affiliations

Constellation Pharmaceuticals (United States)Colorado State University WuXi AppTec (China)C4 Therapeutics (United States)University of Colorado Boulder

About

Christopher G. Nasveschuk is an author at Constellation Pharmaceuticals (United States) specializing in medicine, natural sciences, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	18	1.3K
2	Natural Sciences	14	15	889
3	Biochemistry	10	10	532
4	Engineering	6	6	214
5	Health Sciences	1	1	11

Christopher G. Nasveschuk

Publications

Citations

H-Index

Page 1

	Year	Citations
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials Brian K. Albrecht, Victor Gehling, Michael C. Hewitt, Journal of Medicinal Chemistry ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2016	214
Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas Rishi G. Vaswani, Victor Gehling, Les A. Dakin, Journal of Medicinal Chemistry	2016	214
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon, Chemistry & Biology Hematological MalignancyTumor BiologyLymphoid NeoplasiaMedicineSmall Molecules	2013	154
EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation William D. Bradley, Shilpi Arora, Jennifer Busby, Chemistry & Biology Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyCancer Cell Biology	2014	148
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains Terry D. Crawford, Vickie Tsui, E. Megan Flynn, Journal of Medicinal Chemistry Molecular BiologyChemical BiologyPharmaceutical ChemistryBiological RoleMedicinal Chemistry	2016	117
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637) Alexander M. Taylor, Alexandre Côté, Michael C. Hewitt, ACS Medicinal Chemistry Letters Drug TargetChemical BiologyCancer BiologyMedicinal ChemistryAnti-cancer Agent	2016	111
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors Victor Gehling, Michael C. Hewitt, Rishi G. Vaswani, ACS Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBioorganic ChemistryBiochemistryNatural Sciences	2013	103
The [1, 3] O-to-C rearrangement: opportunities for stereoselective synthesis Christopher G. Nasveschuk, Tomislav Rovis Organic & Biomolecular Chemistry Molecular RearrangementsCross-coupling ReactionEngineeringAlkene MetathesisChemical Transformation	2007	87
A Concise Total Synthesis of Largazole, Solution Structure, and Some Preliminary Structure Activity Relationships Christopher G. Nasveschuk, Dana Ungermannova, Xuedong Liu, Organic Letters	2008	75
Largazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1) Dana Ungermannova, Seth J. Parker, Christopher G. Nasveschuk, PLoS ONE	2012	65

Page 1